Ness Ziona, Israel – March 7, 2016 –

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that BiondVax’s CEO, Dr. Ron Babecoff, will present at the Annual Roth Conference to be held March 13 – 16, 2016 at the Ritz Carlton Hotel in Dana Point, California.

Dr. Babecoff will discuss recent updates and share BiondVax’s corporate presentation on Wednesday, March 16, 2016 at 9am Pacific Time.  The presentation will be available for download from the investor relations section of BiondVax’s website. There will also be an opportunity for investors to meet one-on-one with Dr. Babecoff at the conference on Tuesday, March 15.

Management will also be meeting with analysts and investors in Boca Raton, Florida on Monday, March 14 and in New York City on Thursday, March 17.

Those wishing to meet with Dr. Babecoff are invited contact the Investor Relations team at BiondVax at biondvax@gkir.com.

About BiondVax Pharmaceuticals Ltd

BiondVax is a biopharmaceutical company developing a universal flu vaccine. The vaccine is designed to provide multi-season protection against most seasonal and pandemic human influenza virus strains. BiondVax’s proprietary technology utilizes a unique combination of conserved and common peptides from influenza virus proteins, activating both arms of the immune system for a cross-protecting and long-lasting effect. BiondVax is traded on NASDAQ: BVXV and TASE: BVXV. For more information, please visit www.biondvax.com.

For further information, please contact:

Company Contact
Joshua Phillipson, Business Development  Manager
+972-8-930-2529 x5105
j.phillipson@biondvax.com

Investor Relations Contact
GK Investor Relations
Kenny Green, Partner
+1 646 201 9246
kenny@biondvax.com

###